| Expression pattern: |
UP |
| Associated gene: |
RACGAP1, METTL3, IGF2BP1, Ago2, PI3K/Akt pathway |
| Associated microRNA: |
miR-320d |
| Biological function: |
Promotes OC cell proliferation, migration and invasion; supports tumor growth in vivo; acts as an oncogene and is associated with poor prognosis. |
| Molecular mechanism: |
METTL3/IGF2BP1-mediated m6A modification maintains circASXL1 stability and increases its expression; circASXL1 functions as a ceRNA that sequesters miR-320d, upregulates RACGAP1, and activates the PI3K/Akt pathway. |
| Biological pathway or process: |
PI3K/AKT (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (promotes); m6A modification (promotes); mRNA stability (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; MeRIP / MeRIP-seq; Transfection; MTT; Colony Formation Assay; Wound Healing Assay; Transwell Assay; In Vivo Animal Model; Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Upregulation of circASXL1 was associated with poor prognosis in OC patients; high expression correlated with FIGO stage and lymph node metastasis; circASXL1 may be a novel diagnostic biomarker and therapeutic target for OC. |
| Description: |
circASXL1 is up-regulated in ovarian cancer tissues and cells, and high expression is associated with poor prognosis. METTL3/IGF2BP1-mediated m6A modification stabilizes circASXL1, which promotes proliferation, migration, invasion, and xenograft tumor growth by sponging miR-320d to increase RACGAP1 and activate PI3K/Akt signaling. |
| Confidence score: |
0.8438 |